Risankizumab Versus Placebo in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment in the Russian Federation (IMMpress)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IMMPRESS
- Sponsors AbbVie
- 21 Dec 2018 Planned End Date changed from 7 Feb 2020 to 9 Dec 2019.
- 21 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2018 Status changed from not yet recruiting to recruiting.